Search

Background: One of the complications of multiple sclerosis (MS) is cognitive impairment (CI). The prevalence of CI is reported variously in previous studies. The goal of this systematic review and meta-analysis to estimate pooled prevalence of CI in patients with MS and also the prevalence of CI based on the type of applied test. Methods: Two independent researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar as well as gray literature (conference abstracts, references of the references) which were published before up January 2022. Results: We found 4089 articles by literature search, after deleting duplicates 3174 remained. Ninety articles remained for meta-analysis. The pooled prevalence of CI using all types of tests was 41% (95% CI: 38-44%) (I2=91.7%, p<0.001). The pooled prevalence of CI using BRB test was 39% (95%CI: 36-42%) (I2=89%, p<0.001). The pooled prevalence of CI using BICAMS was 44% (95%CI: 37-51%, I2=95.4%, p<0.001). The pooled prevalence of CI using MACFIMS was 44% (95% CI: 36-53%) (I2=89.3%, p<0.001). Conclusions: The pooled prevalence of cognitive impairment in patients with MS is estimated as 41%, so CI it should be considered by clinicians. [ABSTRACT FROM AUTHOR]

Background: There is a rising trend in the use of herbal stem cell remedies among the populace due to the belief that such remedies have all-encompassing health benefits, and without side effects. However, there is little or no scientific data reported on their safety profile. This study addressed the toxicological effects of STC-30, one of the popular polyherbal stem cell remedies used in several countries of the world including Nigeria, Ghana, Australia, among others. Methods: The inhibitory activity of thymol and the nano-preparations were evaluated qualitatively versus Metronidazole against T. vaginalis in TYI-S33 culture medium. The live T. vaginalis parasites were counted on a hemocytometer, the inhibition rate was assessed and the data analyzed statistically. Results: Thymol and its two nanopreparations at varying concentrations inhibited T. vaginalis in culture after 24, 48, or 72 hours of incubation. The inhibition of T. vaginalis was also achieved in culture with Metronidazole at 65 μg/ml. Conclusion: The percent inhibition of T. vaginalis by thymol and its nanopreparations depended on the duration of incubation and the concentration. Thymol and its nanoliposome preparation showed a lower inhibitory effect (IC50) on T. vaginalis than that of the thymol nanoparticles after 24 or 48 hours of treatment. However, the efficacy of the three thymol forms did not significantly differ after 72 hours of treatment. [ABSTRACT FROM AUTHOR]

INTRODUCTION: Disasters affected the primary health care system in many ways. Maintaining primary health care services is a challenging issue during disasters such as epidemics. A review was conducted to study the lessons learned and successful experiences of other countries in opposing the spread of infectious diseases using the capacity of primary health care. MATERIAL AND METHODS: The present study is a comprehensive review of countries' experiences, successful models, and structural components for development of a model for Iran. A systematic search with suitable keywords was conducted in many databases including web of science, PubMed, Scopus, Science Direct, Google Scholar, and Persian databases; Magiran, and SID. RESULTS: The results showed that generally, the successful actions of countries in case of emergency are divided into disaster cycles including preparedness, response, and recovery. PHC can help health systems to identify new epidemics through surveillance system as an early warning system. Because of the importance of continuity of care in primary health care facilities, business continuity plans are needed. CONCLUSIONS: In order to use the consequences and play an effective role in this field, Iran should use the country's capacity and inter-sectoral cooperation to establish a comprehensive system for telemedicine programs Providing people with doctors and health professionals can strengthen the performance of the primary health care system finally can strengthen the performance of the primary health care system. [ABSTRACT FROM AUTHOR]

Natural resources have long played a prominent part in conventional treatments as a parental source due to their multifaceted functions and lesser side effects. The diversity of marine products is a significant source of possible bioactive chemical compounds with a wide range of potential medicinal applications. Marine organisms produce natural compounds and new drugs with unique properties are produced from these compounds. A lot of bioactive compounds with medicinal properties are extracted from marine invertebrates, including Peptides, Alkaloids, Terpenoids, Steroids. Thus, it can be concluded that marine ecosystems are endowed with natural resources that have a wide range of medicinal properties, and it is important to examine the therapeutic and pharmacological capabilities of these molecules. So, finding particular inhibitors of the COVID-19 in natural compounds will be extremely important. Natural ingredients, in this light, could be a valuable resource in the progression of COVID-19 therapeutic options. Controlling the immunological response in COVID-19 patients may be possible by addressing the PI3K/Akt pathway and regulating T cell responses. T cell effector activity can be improved by preventing anti-viral exhaustion by suppressing PI3K and Akt during the early anti-viral response. The diversity of marine life is a significant supply of potentially bioactive chemical compounds with a broad range of medicinal uses. In this study, some biologically active compounds from marine organisms capable of inhibiting PI3K/AKT and the possible therapeutic targets from these compounds in viral infection COVID-19 have been addressed. [ABSTRACT FROM AUTHOR]

Background: Global vaccination against COVID-19 will help nations to overcome the pandemic stage as soon as possible. Guillain--Barré syndrome (GBS) is an acute immune-mediated inflammatory disease of the peripheral nerves (PNS) that is reported as a complication of both COVID-19 and vaccines. Up to now, case reports regarding the incidence of GBS have been reported after different COVID-19 vaccines worldwide. So, the aim of this systematic review and meta-analysis is to estimate the pooled incidence of GBS after COVID-19 vaccination. Methods: Two expert researchers conducted a systematic search in PubMed, Scopus, EMBASE, Web of Science, Google Scholar as well as gray literature in order to find relevant articles published before September 2022. Results: After deleting duplicates, we found 1021 articles, of which 458 studies were further evaluated. A final number of 21 studies remained for meta-analysis, with most of those being from the USA, UK and Mexico. Follow-up duration was between 21-42 days. Out of the total number of 2.35x109 patients included in the final meta-analysis, 3654 subjects developed GBS after vaccination, most of whom were males. Incidence of GBS per million ranged between 0.23 and 9.8. The pooled incidence of GBS following vaccination was 0%. [ABSTRACT FROM AUTHOR]

Coronavirus (COVID-19) is a worldwide epidemic. Although the main target of COVID-19 is the respiratory system, it is known that the virus can cause neurological complications. Previous studies have shown that its neurological manifestations are usually seen in critically ill patients. In this study, we introduced patients who developed COVID-induced encephalitis despite their good general condition and mild symptoms. The only symptoms of encephalitis in these patients were cognitive impairment, that persisted for more than 6 months. This disorder was confirmed by Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG) test results in patients. While previous studies have shown that COVID-induced cognitive impairment improves over time. Therefore, it is recommended that the diagnosis and treatment of encephalitis be considered in patients with COVID-19 who have mild cognitive and behavioral symptoms. [ABSTRACT FROM AUTHOR]

Background: Primary dysmenorrhea is a common gynecological disorder that affects many women of reproductive age. Ginger, a widely used spice with anti-inflammatory properties, has been suggested as a potential treatment for the painful cramps associated with this condition. Objective: The aim of this systematic review and meta-analysis was to evaluate the efficacy of ginger for pain management in primary dysmenorrhea. Methods: Our systematic review was registered in Prospero (CRD42023418001). Six English (PubMed, Scopus, Web of Science, PsycINFO, CINAHL complete, and Cochrane) and one Persian electric database (SID) was searched up to May 2023 for English or Persian studies that measure the effect of ginger on pain in dysmenorrhea. The Cochrane tool was used to assess the risk of bias of the included studies. Random effects meta-analyses were performed to obtain standardized mean differences (SMD) and 95% confidence intervals (CI). Results: Out of the 804 articles initially identified from the search, 24 were included for qualitative analysis and 12 for quantitative analysis after a full-text evaluation. The combined results of the studies indicate that ginger is notably more effective than placebo in reducing both the intensity (SMD = -1.13; 95% CI = -1.59 to -0.68, I 2 = 81.05%) and duration of pain (SMD = -0.29; 95% CI = -0.46 to -0.12). There were no differences between ginger and nonsteroidal anti-inflammatory drugs (NSAIDs) (SMD = 0.01; 95% CI = -0.24 to 0.25), or exercise (SMD = 0.06; 95% CI = -0.66 to 0.78) for pain intensity. Safety-related data were infrequently reported. Conclusions: The results of this meta-analysis suggest that ginger can effectively reduce pain associated with dysmenorrhea. The findings are limited due to risk of bias in the included studies and the unclear risk-benefit ratio.